AskGene, a clinical-stage biopharmaceutical company focusing on immunotherapies for cancers and autoimmune diseases, closed a $20 million series A financing round in May, led by Qiming Venture Partners and TF Capital. With the funding, AskGene, which is dually based in Camarillo and China, will be focusing on building out its product pipeline. According to the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
